Skip to Content
Also part of the UPMC family:
Monoclonal Antibodies Provider Banner
Monoclonal Antibodies Provider Mobile

Monoclonal Antibody Administration

For Providers: Ordering Monoclonal Antibody Administration for Patients

If you are a non-UPMC provider and would like to order the Monoclonal Antibody Administration for a patient under your care, and unable to place orders in UPMC’s electronic medical record, please:

Your patients can learn more and see if they qualify for treatment by calling 866-804-5251.

COVID-19 Treatment: Monoclonal Antibody Administration

UPMC is one of the few health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.

This one-time administration may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.

UPMC is using monoclonal antibody administration treatment products in outpatient infusion center locations throughout western, central, and north central PA. These include:

Casirivimab & Imdevimab, Manufacturer – Regeneron
Casirivimab and Imdevimab EUA Fact Sheet for Providers


GSK Sotrovimab, Manufacturer – GlaxoSmithKline
GSK Sotrovimab EUA Fact Sheet for Providers


Eli Lilly Bamlanivimab & Etesevimab
GSK Sotrovimab EUA Fact Sheet for Providers

UPMC can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment.

Prioritization Guidelines

We follow the FDA guidelines to provide monoclonal antibodies, which are in limited supply, to those at greatest risk of severe illness and death from COVID-19.

Monoclonal Antibody Administration: Indications for Use

IMPORTANT!

  • Patient must still be symptomatic and within the established timeframe
  • If symptoms have resolved or if the patient now requires new or escalating oxygen therapy, do not refer the patient for treatment

Eligibility criteria are:

  • Test positive for COVID-19 (PCR or antigen test), AND:
  • Have had mild-moderate symptoms for 7 days or less (must still be symptomatic), AND:
  • Age ≥ 65 years OR
  • Age 12 years and older weighing at least 40 kg with at least one high risk criterion:
    • Pregnancy
    • Chronic kidney disease
    • Cardiovascular disease (including congenital heart disease, hypertension)
    • Diabetes
    • Down syndrome
    • Dementia
    • Liver disease
    • Current or former smoker
    • Current or history of substance abuse
    • Immunosuppressive disease or immunosuppressive treatment
    • History of stroke or cerebrovascular disease
    • Chronic lung disease
    • Sickle cell disease
    • Neurodevelopmental disorders (e.g., cerebral palsy)
    • Having a medical-related technological dependence (e.g., tracheostomy, gastrostomy)

*Symptoms include: Fever, cough, sore throat, malaise, headache, muscle pain, GI symptoms, or shortness of breath with exertion.

Monoclonal Antibody Administration: Limitations of Use

Not authorized for use in patients:

  • Who are hospitalized due to COVID-19
  • Who require oxygen therapy due to COVID-19
  • Who require an increase in baseline oxygen flow rate due to COVID-19

Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.

Monoclonal Antibody Administration: Considerations

With many medications, there is a risk of allergic reaction, albeit reactions to these medications requiring discontinuation are very rare. The infusion centers have trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.

COVID-19 Vaccines and Monoclonal Antibody Administration

Per the CDC, COVID-19 vaccination should be deferred for at least 90 days after receiving monoclonal antibody administration.

Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after vaccination, if the patient is a candidate based on COVID-19 disease.

Information for Patients

Check out our web page for information for patients about monoclonal antibody treatment.